Targovax have one collaboration trial ongoing:
Targovax has a collaboration trial with US-based Cancer Research Institute (CRI), Ludwig Cancer Research (Ludwig, trial sponsor) and AstraZeneca in patients who have metastatic colorectal cancer and have failed prior standard therapies.
It’s a single arm, open-label, multi-center phase 1/2 trial, where ONCOS-102 is intraperitoneally administered in combination with Imfinzi (durvalumab, an anti-PD-L1 antibody), to patients who have metastatic colorectal cancer with peritoneal carcinomatosis and have failed prior standard therapies. The trial will assess the safety, biologic and anti-tumor activity of the combination, and is financed by Cancer Research Institute (CRI) and run by Ludwig Cancer Research, and Targovax was selected to participate with ONCOS-102 as the virus of choice for this trial. Targovax retains all commercial rights to ONCOS-102 in this collaboration.
The trial completed recruitment in June 2021 with a total of 33 patients enrolled with 30 patients treated with the full dose ONCOS-102 and durvalumab combination.
The safety reviews during the dose escalation phase were completed with no dose limiting toxicities, and the combination showed good tolerability. Data from this trial are expected in the first half of 2022.